Combination treatment of PARP inhibitor, BMN 673 and DNMT inhibitor, Azacytidine: A potential therapy for BRCA negative and positive, triple negative breast cancers

被引：0
|
作者：
Chowdhury, Khadiza [1 ]
Lapidus, Rena G. [1 ]
Choi, Eun Yong [1 ]
Baylin, Stephen [2 ]
Rassool, Feyruz V. [1 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
[2] Johns Hopkins Univ, Baltimore, MD USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2948
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2948
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PI3K Inhibitor Increased Radiosensitizing Effect of PARP Inhibitor in BRCA-Proficient Triple Negative Breast Cancer Cells
    Kim, I. A.
    Jang, N. Y.
    Kim, D. H.
    Cho, B. J.
    Choi, E. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E533 - E534
  • [22] PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers
    Stebbing, Justin
    Ellis, Paul
    Tutt, Andrew
    FUTURE ONCOLOGY, 2010, 6 (04) : 485 - 486
  • [23] PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers
    Luo, Linjie
    Keyomarsi, Khandan
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (06) : 607 - 631
  • [24] Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.
    Cotte, Alexia
    Beniey, Michele
    Haque, Takrima
    Bechir, Nelly
    Hubert, Audrey
    Diallo, Korotoum W.
    Tran-Thanh, Danh
    Hassan, Saima N.
    CANCER RESEARCH, 2021, 81 (13)
  • [25] Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer
    Gong, Rong
    Ma, ZhongYe
    He, LinHao
    Jiang, ShiLong
    Cao, DongSheng
    Cheng, Yan
    CHEMICO-BIOLOGICAL INTERACTIONS, 2023, 382
  • [26] Sigma-2 ligands sensitize triple negative breast cancer cells to PARP inhibitor treatment
    Zeng, Chenbo
    Mankoff, Julia
    Mach, Robert H.
    CANCER RESEARCH, 2015, 75
  • [27] Combinational treatment of biguanides and fatty acid β-oxidation inhibitor in triple-negative breast cancers
    Park, J. H.
    Jung, K. H.
    Vithayathil, S.
    Jia, D.
    Kaipparettu, B. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [28] MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells
    Zeng, Xiaoqi
    Jiang, Shanshan
    Ruan, Simin
    Guo, Zhaoze
    Guo, Jingyun
    Liu, Minfeng
    Ye, Changsheng
    Dong, Jianyu
    MOLECULAR MEDICINE REPORTS, 2021, 24 (02)
  • [29] Novel combination therapy of DNA methyltransferase inhibitor guadecitabine (SGI-110) and PARP inhibitor talazoparib (BMN-673) for BRCA-proficient high-grade serous ovarian cancer
    Pulliam, Nicholas
    Taverna, Pietro
    Lyons, John
    Nephew, Kenneth P.
    CANCER RESEARCH, 2017, 77
  • [30] SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
    Lu, Zhen
    Mao, Weiqun
    Yang, Hailing
    Santiago-O'Farrill, Janice M.
    Rask, Philip J.
    Mondal, Jayanta
    Chen, Hu
    Ivan, Cristina
    Liu, Xiuping
    Liu, Chang-Gong
    Xi, Yuanxin
    Masuda, Kenta
    Carrami, Eli M.
    Chen, Meng
    Tang, Yitao
    Pang, Lan
    Lakomy, David S.
    Calin, George A.
    Liang, Han
    Ahmed, Ahmed A.
    Vankayalapati, Hariprasad
    Bast, Robert C., Jr.
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (11):
12345